Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias

References

• WindholzMThe Merck Index14th edNew JerseyMerck & Co2006
   Google Scholar
• DreyerEBZhangDLiptonSATranscriptional or translational inhibition blocks low dose NMDA-mediated cell deathNeuroreport1995669429447612888
   PubMed Web of Science ®Google Scholar
• BonfocoEKraincDAnkarcronaMNicoteraPLiptonSAApoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell culturesProc Natl Acad Sci U S A19959216716271667638161
   PubMed Web of Science ®Google Scholar
• SucherNJLiptonSADreyerEBMolecular basis of glutamate toxicity in retinal ganglion cellsVision Res19973724348334939425525
   PubMed Web of Science ®Google Scholar
• KohJYYangLLCotmanCWBeta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damageBrain Res199053323153202289145
   PubMed Web of Science ®Google Scholar
• HarkanyTAbrahamITimmermanWBeta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalisEur J Neurosci20001282735274510971616
   PubMed Web of Science ®Google Scholar
• ZeevalkGDNicklasWJEvidence that the loss of the voltage-dependent Mg2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolismJ Neurochem1992594121112201402878
   PubMed Web of Science ®Google Scholar
• LiptonSANicoteraPCalcium, free radicals and excitotoxins in neuronal apoptosisCell Calcium19982323165171
   Web of Science ®Google Scholar
• LiptonSAParadigm shift in neuroprotection by NMDA receptor blockade: memantine and beyondNat Rev Drug Discov20065216017016424917
   PubMed Web of Science ®Google Scholar
• ChenHSLiptonSAMechanism of memantine block of NMDA-activated channels in rat retinal ganglion cellsJ Physiol1997499Pt 127499061638
   PubMed Web of Science ®Google Scholar
• ChenHSPellegriniJWAggarwalSKOpen-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJ Neurosci19921211442744361432103
   PubMed Web of Science ®Google Scholar
• BresinkIBenkeTACollettVJEffects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cellsBr J Pharmacol199611921952048886398
   PubMed Web of Science ®Google Scholar
• VorwerkCKLiptonSAZurakowskiDHymanBTSabelBADreyerEBChronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantineInvest Ophthalmol Vis Sci1996378161816248675405
   PubMed Web of Science ®Google Scholar
• PellegriniJWLiptonSADelayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicityAnn Neurol19933344034078098195
   PubMed Web of Science ®Google Scholar
• WinbladBPoritisNMemantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry199914213514610885864
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerAMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med2003348141333134112672860
   PubMed Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGTMemantine treatment in patients with moderate to seere Alzheimer’s disease already receiving donepezil: a randomized controlled trialJAMA2004291331732414734594
   PubMed Web of Science ®Google Scholar
• van DyckCHSchmittFAOlinJTMemantine MEM-MD-02 Study GroupA responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezilAm J Geriatr Psychiatry200614542843716670247
   PubMed Web of Science ®Google Scholar
• WaldemarGHyvarinenMJosiassenMKKornerALehtoHWtterbergPTolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry200823997998118229874
   PubMed Web of Science ®Google Scholar
• WilcockGKBallardCGCooperJALoftHMemantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disase: a pooled analysis of 3 studiesJ Clin Psychiatry200869334134818294023
   PubMed Web of Science ®Google Scholar
• GauthierSLoftHCummingsJImprovement in behavrioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysisInt J Geriatr Psychiatry200823553754518058838
   PubMed Web of Science ®Google Scholar
• GrossbergGTPejovicVMillerMLGrahamSMMemantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s diseaseDement Geriatr Cogn Disord200927216417219194105
   PubMed Web of Science ®Google Scholar
• van DyckCHTariotPNMeyersBMalca ResnickEfor the Memantine MEM-MD-01 Study GroupA 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer diseaseAlzhiemer Dis Assoc Disord2007212136143
   PubMed Web of Science ®Google Scholar
• AtriAShaughessyLWLocasciaJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer’s diseaseAlxheimer Dis Assoc Disord2008223209221
   PubMed Web of Science ®Google Scholar
• LopezOLBeckerJTWahedASLong-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJ Neurol Neurosurg Psychiatry200980660060719204022
   PubMed Web of Science ®Google Scholar
• CummingsJLSchneiderETariotPNGrahamSMMemantine MEM-MD-02 Study GroupBehavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology2006671576316832078
   PubMed Web of Science ®Google Scholar
• FeldmanHHSchmittFAOlinJTMemantine MEM-MD-02 Study GroupActivities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatmentAlzheimer Dis Assoc Disord200620426326817132971
   PubMed Web of Science ®Google Scholar
• SchmittFAvan DyckCHWichemsCHOlinJTfor the Memantine MEM-MD-02 Study GroupCognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysisAlzheimer Dis Assoc Disord200620425526217132970
   PubMed Web of Science ®Google Scholar
• RiepeMWAdlerGIbachBWeinkaufBTracikFGunayIDomain-specific improvement of cognition on memantine in patients with Alzheimer’s disease treated with rivastigmineDement Geriatr Cogn Disord200723530130617356273
   PubMed Web of Science ®Google Scholar
• DautzenbergPLWoutersCJBootsmaJEObservations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of ADInt Psychogeriatr200618117918116734932
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerASchmittFFerrisSMobiusHJA 24- week open-label extension study of memantine in moderate to severe Alzheimer diseaseArch Neurol2006631495416401736
   PubMedGoogle Scholar
• WinbladBJonesRWWirthYStofflerAMobiusHJMemantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomized clinical trialsDement Geriatr Cogn Disord2007315775782
   Google Scholar
• WilkinsonDAndersenHFAnalysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s diseaseDement Geriatr Cogn Disord200724213814517622761
   PubMed Web of Science ®Google Scholar
• EmreMMecocciPStenderKPooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s diseaseJ Alzheimers Dis200814219319918560130
   PubMed Web of Science ®Google Scholar
• RiveBVercellettoMDamierFDCochranJFrancoisCMemantine enhances autonomy in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry200419445846415156547
   PubMed Web of Science ®Google Scholar
• PaskavitzJFGunstadJJSamuelJEClock drawing and frontal lobe behavioral effects of memantine in Alzheimer’s disease: a rater-blinded studyAm J Alzheimers Dis Other Demen2006216449454
   Google Scholar
• GauthierSWirthYMobiusHJEffects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuro-psychiatric Inventory (NPI) data of two randomized, controlled studiesInt J Geriatr Psychiatry200520545946415852444
   PubMed Web of Science ®Google Scholar
• FerrisSSchneiderLFarmerMKayGCrookTA double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI)Int J Geriatr Psychiatry200722544845517117395
   PubMed Web of Science ®Google Scholar
• PeskindERPotkinSGPomaraNMemantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trialAm J Geriatr Psychiatry200614870471516861375
   PubMed Web of Science ®Google Scholar
• PorsteinssonAPGrossbergGTMintzerJOlinJTMemantine MEM-MD-12 Study GroupMemantine treatement in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trialCurr Alzheimer Res200851838918288936
   PubMed Web of Science ®Google Scholar
• BakchineSLoftHMemantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled 6-month studyJ Alzheimers Dis20081319710718334761
   PubMed Web of Science ®Google Scholar
• MobiusHJStofflerAMemantine in vascular dementiaInt Psychogeriatr200315Suppl 120721316191242
   PubMed Web of Science ®Google Scholar
• OrgogozoJMRigaudASStofflerAMobiusHJForetteFEfficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300)Stroke20023371834183912105362
   PubMed Web of Science ®Google Scholar
• KavirajanHSchneiderLSEfficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomized controlled trialsLancet Neurol20076978279217689146
   PubMed Web of Science ®Google Scholar
• LevinOSBatukaevaLASmolentsevaIGAmosovaNAEfficacy and safety of memantine in dementia with Lewy bodiesZh Nevrol Psikhiatr Im S S Korsakova20081085394618577956
   PubMedGoogle Scholar
• SabbaghMNHakeAMAhmedSFarlowMRThe use of memantine in dementia with Lewy bodiesJ Alzheimer’s Dis200574285289
   Web of Science ®Google Scholar
• RidhaBHJosephsKARosserMNDelusions and hallucinations in dementia with Lewy bodies: worsening with memantineNeurology200565348148216087923
   PubMed Web of Science ®Google Scholar
• SchifittoGNaviaBAYiannoutsosCTAdult AIDS Clinical Trial Group (ACTG) 301;700 teams; HIV MRS ConsortiumMemantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy studyAIDS200721141877188617721095
   PubMed Web of Science ®Google Scholar
• RustembegovicAKundurovicZSapcaninASoficEA placebo-controlled study of memantinet (Ebixa) in dementia of Wernicke- Korsakoff syndromeMed Arh200357314915012858653
   PubMedGoogle Scholar
• Diehl-SchmidJForstlHPerneczkyRPohlCKurzAA 6-month, open-label study of memantine in patients with frontotemporal dementiaInt J Geriatr Psychiatry200823775475918213609
   PubMed Web of Science ®Google Scholar
• WenkGLDanyszWMobleySLMK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularisEur J Pharmacol199529332672708666045
   PubMed Web of Science ®Google Scholar
• VolbrachtCvan BeekJZhuCBlomgrenKLeistMNeuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicityEur J Neurosci20061482611262216817864
   PubMed Web of Science ®Google Scholar
• ZhaoXMarszalecWTothPTHuangJYehJZNarahashiTIn vitro galantamine-memantine co-application: mechanism of beneficial actionNeuropharmacology2006517811811191
   Web of Science ®Google Scholar
• GaribovaTLVoroninaTALitvinovaSAKuznetsovaALKul’chikovAEAlesenkoAVFeatures of memantine action profile in cholinergic deficit and intracerebral posttraumatic hematoma (hemorrhagic stroke) models in ratsEksp Klin Farmakol200871281318488899
   PubMedGoogle Scholar
• MoreLGraviusANagelJValastroBGrecoSDanyszWTherapeutically relebant placma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in ratsBehav Pharmacol200819772473418797249
   PubMed Web of Science ®Google Scholar
• StiegPESathiSWarachSLeDALiptonSANeuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal ratEur J Pharmacol19993751311512010443560
   PubMed Web of Science ®Google Scholar
• RaoVLDoganAToddKGBowenKKDempseyRJNeuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in ratsBrain Res200191119610011489449
   PubMed Web of Science ®Google Scholar
• LiuCLinNWuBQiuYNeuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injuryBrain Res2009128217318219501064
   PubMed Web of Science ®Google Scholar
• SinnDILeeSTChuKCombined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhageNeurosci Lett2007411323824217123715
   PubMed Web of Science ®Google Scholar
• RojasJCSaavedraJAGonzalez-LimaFNeuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenoneBrain Res2008121520821718486118
   PubMed Web of Science ®Google Scholar
• ItoYNakamuraSTanakaHShimazawaMAraieMHaraHMemantine protects against secondary neuronal degeneration in lateral geniculate nucleus and superior colliculus after retinal damage in miceCNS Neurosci Ther200814319220218801112
   PubMed Web of Science ®Google Scholar
• CulmseeCJunkerVKremersWThalSPlesnilaNKrieglsteinJCombination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterolStroke20043551197120215060319
   PubMed Web of Science ®Google Scholar
• JungKHChuKLeeSTAugmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibitionBiochem Biophys Res Commun2009378350751219056343
   PubMed Web of Science ®Google Scholar
• LapchakPAMemantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbitsBrain Res20061088114114716626666
   PubMed Web of Science ®Google Scholar
• BattistaMAHierholzerRKhouzamHRBarlowAO-TooleSPilot trial of memantine in the treatment of posttraumatic stress disorderLancet Neurol20076978279217689146
   PubMed Web of Science ®Google Scholar
• FischerPAJacobiPSchneiderESchonbergerBEffects of intravenous administration of memantine in parkinsonian patientsArzneimittelforschung197727714871489332193
   PubMed Web of Science ®Google Scholar
• SchneiderEFischerPAClemensRBalzereitFFunfgeldEWHaaseHJEffects of oral memantine administration on Parkison symptoms. Results of a placebo-controlled multicenter studyDtsch Med Wochenschr1984109259879906734455
   PubMed Web of Science ®Google Scholar
• MerelloMNouzeillesMICammarotaALeiguardaREffect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized studyClin Neuropharmacol199922527327610516877
   PubMed Web of Science ®Google Scholar
• NikolajsenLGottrupHKristensenAGJensenTSMemantine (a N-methy-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over studyAnesth Analg200091496096611004057
   PubMed Web of Science ®Google Scholar
• SangCNBooherSGilronIParadaSMaxMBDextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trialsAnesthesiology20029651053106111981142
   PubMed Web of Science ®Google Scholar
• SchifittoGYiannoutsosCTSimpsonDMAdult AIDS Clinical Trials Group (ACTG) 301 TeamA placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathyJ Neuroviol2006124328331
   Web of Science ®Google Scholar
• SchleyMTopfnerSWiechKContinuous brachial plexus blockade in combination with the NMDA-receptor antagonist memantine prevents phantom limb pain in acute traumatic upper limb amputeesEur J Pain200711329930816716615
   PubMed Web of Science ®Google Scholar
• MaierCDertwinkelRMansourianNEfficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain – results of a randomized double-blinded, placebo-controlled trialPain2003103327728312791434
   PubMed Web of Science ®Google Scholar
• WiechKKieferRTTopfnerSA placebo-controlled randomized crossover trial of the N-methyl-D-aspartate acid receptor antagonist, memantine, in patients with chronic phantom limb painAnesth Analg200498240841314742379
   PubMed Web of Science ®Google Scholar
• SinisNBirbaumerNGustinSMemantine treatment of complex regional pain syndrome: a preliminary report of six casesClin J Pain200723323724317314583
   PubMed Web of Science ®Google Scholar
• BigalMRapoportASheftellFTepperDTepperSMemantine in the preventive treatment of refractory migraineHeadache20084891337134219031499
   PubMed Web of Science ®Google Scholar
• MuhonenLHLonnqvistJJuvaKAlhoHDouble-blind, randomized comparison of memantine and excitalopram for the treatment of major depressive disorder comorbid with alcohol dependenceJ Clin Psychiatry200869339239918348597
   PubMed Web of Science ®Google Scholar
• FergusonJMShingletonRNAn open-label, flexible-dose study of memantine in major depressive disorderClin Neuropharmacol200730313614417545748
   PubMed Web of Science ®Google Scholar
• BrennanBPRobertsJLFogartyKVReynoldsKAJonasJMHudsonJIMemantine in the treatment of binge eating disorder: an open-label, prospective trialInt J Eat Disorder2008416520526
   PubMed Web of Science ®Google Scholar
• KrivoyAWizmanALaorLHellingerNZemishlanyZFischelTAddition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary studyEur Neuropsychopharmacol200818211712117728110
   PubMed Web of Science ®Google Scholar
• CerulloMAAdlerCMStrakowskiSMEliassenJCNasrallahHANasrallahATMemantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI studySchizophr Res2007971329429617851043
   PubMed Web of Science ®Google Scholar
• NiederhoferHGlutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autismJ Clin Psychopharmacol200727331731817502791
   PubMed Web of Science ®Google Scholar
• ChezMGBurtonQDowlingTChangMKhannaPKramerCMemantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerabilityJ Child Neurol200722557457917690064
   PubMed Web of Science ®Google Scholar
• FindlingRLMcNamaraNKStansbreyRJA pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined typeJ Child Adolesc Psychopharmacol2007171193317343551
   PubMed Web of Science ®Google Scholar
• McLeanRProudlockFThomasSDeggCGottlobICongenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentinAnn Neurol200761213013817279539
   PubMed Web of Science ®Google Scholar
• OndoWGMejiaNIHunterCBA pilot study of the clinical efficacy and safety of memantine for Huntington’s diseaseParkinsonism Relat Disord200713745345417046312
   PubMed Web of Science ®Google Scholar
• BeisterAKrausPKuhnWDoseMWeindlAGerlachMThe N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s diseaseJ Neural Transm Suppl20046811712215354397
   PubMedGoogle Scholar
• BisagaAComerSDWardASPopikPKleberHDFischmanMWThe NMDA antagonist memantine attenuates the expression of opioid physical dependence in humansPsychopharmacology2001157111011512037
   PubMed Web of Science ®Google Scholar
• FigueiredoRRLangguthBMello de OliveiraPAparecida de AzevedoATinnitus treatment with memantineOtolaryngol Head Neck Surg2008138449249618359360
   PubMed Web of Science ®Google Scholar
• CollinsEDVosbergSKWardASHaneyMFoltinRWThe effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humansExp Clin Psychopharmacol200715322823717563209
   PubMed Web of Science ®Google Scholar
• VosburgSKHartCLHaneyMFoltinRWAn evaluation of the reinforcing effects of memantine in cocaine-dependent humansDrug Alcohol Depend200579225726016002035
   PubMed Web of Science ®Google Scholar
• ThueraufNLunkenheimerJLunkenheimerBMemantine fails to facilitate partial cigarette deprivation in smokers – no role of memantine in the treatment of nicotine dependency?J Neural Transm2007114335135717043926
   PubMed Web of Science ®Google Scholar
• ZarateCAJrSinghJBQuirozJAA double-blind, placebo-controlled study of memantine in the treatment of major depressionAm J Psychiatry2006163115315516390905
   PubMed Web of Science ®Google Scholar
• EvansSMLevinFRBrooksDJGarawiFA pilot double-blind treatment of memantine for alcohol dependenceAlcohol Clin Exp Res200731577578217378918
   PubMed Web of Science ®Google Scholar
• MuhonenLHLahtiJSinclairDLonnqvistJAlhoHTreatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medicationSubst Abuse Treat Prev Policy200832018834506
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [homepage on the internet]MarylandUS National Library of Medicinec1993–2008 [updated 2009 June 2; cited 2009 June 15]. http://www.clinicaltrials.gov/
   Google Scholar
• GrossbergGTManesFAllegriRA multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. [poster]133rd Annual Meeting of the American Neurological AssociationSeptember 21–24, 2008Salt Lake City, UT, USA Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings This journal is indexed on PubMed Central, MedLine, the American Chemical Society’s ‘Chemical Abstracts Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
   Google Scholar
• JonesRWBayerAInglisFBarkerAPhulRSafety and tolerability of once-daily versus twice-daily memantinet: a randomized, double-blind study in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry200722325826217243195
   PubMed Web of Science ®Google Scholar
• OttBRBlakeLMKaganEResnickMfor the Memantine MEM-MD-11AB Study GroupOpen label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s diseaseJ Neurol2007254335135817345042
   PubMed Web of Science ®Google Scholar
• Frx.com [homepage on the internet]MissouriForest Laboratories, Inc.c2007 [updated 2007 April; cited 2009 June]. http://www.frx.com/pi/Namenda_pi.pdf/
   Google Scholar
• RammesGRupprechtRFerrariUZieglgansbergerWParsonsCGThe N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonize 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in non-competitive mannerNeurosci Lett200130612818411403943
   PubMed Web of Science ®Google Scholar